Notice of Proposed Sale · 144
Illumina, Inc.
ILMNNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- ILLUMINA INC
- Issuer CIK
- 0001110803
- SEC file number
- 001-35406
- Phone
- 8582024500
- Person for whose account securities are to be sold
- SCOTT DAVIES
- Relationships to issuer
- Officer
- Street
- 5200 Illumina Way
- City
- San Diego
- State / country code
- CA
- Postal code
- 92122
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 615 | 119,814.30 | 151,300,000 | 07/30/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 11/05/2024 | Restricted Stock Units | Issuer | 615 | N | 11/05/2024 | N/A |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for SCOTT DAVIES | Common | 06/25/2026 | 615 | 110,700.00 |
| 10b5-1 Sales for SCOTT DAVIES | Common | 05/29/2026 | 615 | 98,400.00 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for SCOTT DAVIES
- Street
- 5200 Illumina Way
- City
- San Diego
- State / country code
- CA
- Postal code
- 92122
Seller — prior-sale row 2, entry 1
- Name
- 10b5-1 Sales for SCOTT DAVIES
- Street
- 5200 Illumina Way
- City
- San Diego
- State / country code
- CA
- Postal code
- 92122
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 07/30/2026
- Signed
- /s/ Scott Davies
- Plan adoption dates
- 11/21/2025
Company context
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Current securities
Historical securities (1)
Recent company filings
- 10-Q filingOct 30, 2026
- Results of Operations and Financial ConditionOct 29, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementOct 13, 2026
- SCHEDULE 13G - filed by FMR LLC regarding ILLUMINA, INC.Oct 7, 2026
- 4 filingSep 9, 2026